SCHEMBL451332

SCHEMBL451332

C1=Cc2ccccc2SS1

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL133304 0.74
SCHEMBL3685811 0.73 NPC1 (0.33)
SCHEMBL4742301 0.67 TRPA1 (0.50) TRPA1
SCHEMBL4862177 0.65
SCHEMBL5058579 0.64 GAA (0.35)
SCHEMBL219846 0.63
SCHEMBL348197 0.63
Water SCHEMBL19744946 0.62
SCHEMBL563542 0.62 KDM4E (0.35)
Water SCHEMBL19745732 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 627 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3885337-B1 FTO INHIBITORS NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) 2025-01-15 EP claimed
EP-3885337-A1 FTO INHIBITORS National Institute Of Biological Sciences, Beijing (CN) 2021-09-29 EP claimed
US-20210238127-A1 FTO Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-08-05 US claimed
US-10988440-B2 FTO inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-04-27 US claimed
US-20200148628-A1 FTO Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-05-14 US claimed
US-20180118665-A1 FTO Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2018-05-03 US claimed
EP-3303283-A1 FTO INHIBITORS National Institute Of Biological Sciences, Beijing (CN) 2018-04-11 EP claimed
WO-2016206573-A1 FTO INHIBITORS NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2016-12-29 WO claimed
EP-2662351-B1 Alkylated heterocyclic reaction products useful as antioxidants SI GROUP INC (US) 2016-03-30 EP claimed
EP-2084142-B1 ALKYLATED HETEROCYCLIC REACTION PRODUCTS USEFUL AS ANTIOXIDANTS SI GROUP INC (US) 2016-03-23 EP claimed
EP-2662351-A1 Alkylated heterocyclic reaction products useful as antioxidants Albemarle Corporation (US) 2013-11-13 EP claimed
US-8410084-B2 Alkylated heterocyclic reaction products useful as antioxidants ALBEMARLE CORPORATION (US) 2013-04-02 US claimed
EP-1852420-B1 Indole compounds for treating respiratory disorders ONO PHARMACEUTICAL CO (JP) 2012-10-17 EP claimed
US-8153625-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-10 US claimed
US-20100221646-A1 HOLOGRAPHIC RECORDING MEDIUM KABUSHIKI KAISHA TOSHIBA (JP) 2010-09-02 US claimed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US claimed
US-7402580-B2 Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-07-22 US claimed
US-12630510-B2 EP2 antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2026-05-19 US disclosed
US-4944790-A PLANT SAFENING AGENTS FOR USE WITH CERTAIN HERBICIDES CIBA-GEIGY CORPORATION (US) 1990-07-31 US disclosed
US-4425161-A Thermochromic materials PILOT INK COMPANY, LTD., (JP) 1984-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118665-A1 FTO Inhibitors FTO, ALKBH3, ALKBH1 TRPA1 3013/4885
US-20210238127-A1 FTO Inhibitors FTO, ALKBH3, ALKBH1 TRPA1 3013/4885
US-12630510-B2 EP2 antagonist PTGER2, PTGER1, PTGER4 TRPA1 542/4885
US-20200148628-A1 FTO Inhibitors FTO, ALKBH3, ALKBH1 TRPA1 3013/4885
US-10988440-B2 FTO inhibitors FTO, ALKBH3, ALKBH1 TRPA1 3013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.